What is Bronchogen?
Bronchogen is one of a series of very short synthetic peptides developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Each was designed with a particular organ or tissue in mind. Bronchogen is the version aimed at the bronchi, the airways leading into the lungs, and at lung tissue itself. It is a chain of only four amino acids.
Bronchogen is often discussed alongside epithalon, the best known compound from the same program. Unlike approved medicines, it has not been through the stages of clinical testing used to judge whether a drug works and is safe, so most of what is known about it comes from laboratory and animal work.
How does Bronchogen work?
In a study of human bronchial lining cells grown in the lab, Khavinson's group reported that Bronchogen changed the activity of genes involved in airway cell development, including NKX2-1 and SCGB1A1, and of genes for mucins and surfactant protein A, part of the protective film that lines the air sacs. Markers of cell division rose, most of all in older cell cultures, and a marker linked to cell death fell. The group also reported that it binds DNA in test-tube experiments. How this translates to a living lung is unknown.
What has research looked at?
- Lung cell cultures
- The group reported changes in gene activity, cell division and survival markers in human bronchial cells, with the largest effect on cell division in older cultures.
- Lung injury in rats
- In rat models of bacterial lung inflammation, lung scarring and toxic lung damage, the developers reported protective effects on lung tissue.
- Airway lining protection
- Reported increases in mucin and surfactant protein genes led the group to suggest it may protect the airway lining, an idea not tested in people.
- Human studies
- No large randomized controlled trials of Bronchogen in people have been published in international journals.
Bronchogen's evidence base is thin even by the standards of experimental peptides. Almost all the studies come from Khavinson's group and its collaborators, have not been independently repeated, and were done in cells or rats. Claims that it improves asthma, COPD or lung damage in people are not supported by human data.
What is a peptide bioregulator?
Khavinson's group uses the term peptide bioregulator for very short peptides, often two to four amino acids, that they believe can enter cells, reach the nucleus and bind DNA, changing which genes are active in a given tissue. They report that these effects are tissue specific and stronger in older cells. Researchers outside the group have done little to test this model, so it remains a hypothesis from one research program rather than an established part of biology.
Side effects and cautions
There is no meaningful published data on Bronchogen's side effects in people. Safety findings in animals, where reported, do not establish safety in humans. The biggest practical risk is for people with asthma, COPD or other lung disease relying on it in place of established care. Anyone with a lung condition should talk to a qualified clinician.
- No human safety data
- Side effects in people have not been studied in controlled trials, so the risks are unknown.
- Lung disease
- Asthma, COPD and other lung conditions can worsen quickly, and there is no evidence Bronchogen can replace established care.
- Pregnancy and young people
- There is no safety information for pregnancy, breastfeeding or children.
Further reading
This page summarizes the research in plain words. To read the studies yourself:
- Published studies on Bronchogen PubMed, US National Library of Medicine
